Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Brodifacoum is a highly potent second-generation anticoagulant rodenticide of the 4-hydroxycoumarin class. It acts as a vitamin K antagonist by inhibiting the enzyme vitamin K epoxide reductase, thereby blocking the synthesis of vitamin K–dependent clotting factors (II, VII, IX, and X), leading to uncontrolled bleeding in target organisms. Brodifacoum is characterized by its extremely high toxicity to mammals and birds and an exceptionally long biological half-life (up to nine months in humans), which increases risks of secondary poisoning and environmental persistence. It is used primarily for rodent control but has also been employed against larger pests such as possums[2][6]. Human exposure can result in severe coagulopathy requiring prolonged treatment with vitamin K[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on brodifacoum.